Business Wire

QUECTEL-WIRELESS

10.1.2024 18:01:36 CET | Business Wire | Press release

Share
Quectel announces industry-first certification of satellite communication module on Skylo network

CES – Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the successful certification of Quectel's NTN-enabled module, the CC660D-LS, for use on the network by Skylo, the leading non-terrestrial network (NTN) service provider. The module is the first to be certified by Skylo for use on its network and enables seamless and reliable IoT-NTN connectivity for any standard device that incorporates the module and has a view of the sky.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110653580/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel announces industry-first certification of satellite communication module on Skylo network (Photo: Business Wire)

Quectel has developed the CC660D-LS module specifically to provide dependable and efficient, two-way, satellite communication capabilities. With the module's certification on the Skylo network, businesses and organizations can harness the power of Skylo's ubiquitous satellite connectivity to enable IoT applications in remote and challenging environments, ensuring that data is transmitted securely and reliably.

The CC660D-LS module provides a range of flexible connectivity options, encompassing L-band, S-band, and Band 23 connections. Notably, this module is equipped to support 3GPP Release 17 IoT non-terrestrial network (IoT-NTN) connections, reflecting its advanced capabilities. Prioritizing reliable connectivity, the CC660D-LS module excels in facilitating two-way communication. Furthermore, the module extends its support to both IP and Non-IP service networks. This dual capability ensures not only enhanced connectivity but also heightened service availability. The CC660D-LS module stands as a comprehensive solution for robust and versatile connectivity needs.

"We are delighted that Skylo has certified our NTN Satellite Communication Module for its network," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "This certification reflects our commitment to delivering high-quality satellite communication solutions to our customers worldwide. By collaborating with Skylo, we enable businesses to unlock new opportunities and achieve their IoT goals, regardless of where they are located."

The Skylo certification process involved rigorous testing and evaluation to ensure that the CC660D-LS module meets stringent quality and performance standards, including 3GPP Release-17 standards and Skylo's Standards Plus qualifications. Skylo's network is designed to provide global coverage, ensuring that IoT devices equipped with Quectel's module can stay connected in areas with limited terrestrial infrastructure.

"We are excited to welcome Quectel's CC660D-LS module to our ecosystem of certified devices," said Dr Andrew Nuttall, CTO and Co-Founder of Skylo. "This certification is a testament to our commitment to providing the most reliable and expansive satellite based IoT connectivity. By partnering with industry leaders like Quectel, we empower device manufacturers of all types to expand their IoT applications, add additional review streams, and deliver a superior customer experience that requires no change in user behavior."

Quectel's CC660D-LS module is suitable for a wide range of applications, including asset tracking, fleet management, agriculture, maritime, and more. The module's compact design and low-power consumption make it an ideal choice for battery-powered IoT devices that require long-term, uninterrupted connectivity.

Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle.

IoT developers now can streamline their development process by combining Quectel modules with Quectel's antennas and pre-certification services, effectively reducing both costs and time-to-market for their IoT devices. For the CC660D-LS satellite module, Quectel offers the YECN028AA and YFCA011AA antennas, providing developers with versatile options to enhance connectivity and expedite the deployment of their innovative solutions.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

About Skylo

Skylo Technologies is an NTN service provider based in Mountain View, CA, offering a service that allows cellular modems and devices to connect directly over existing satellites. Devices connected over satellite are managed and served by Skylo’s commercial NTN vRAN, featuring a 3GPP standards-based cloud-native base station and core. Skylo works with existing satellite operators, terrestrial mobile network operators, and device makers to provide subscribers an anywhere, anytime connectivity solution that seamlessly roams between terrestrial and satellite networks. Skylo’s focus is on enabling connected services for people outdoors and connected workflows for machines at work across critical industries such as agriculture, maritime, logistics, mining, and others, in addition to mass-market consumer devices. For more information, visit www.skylo.tech, contact info@skylo.tech, or follow us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240110653580/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye